Echosens and Boehringer Ingelheim have expanded their collaboration aimed at expediting progress in metabolic ...

A novel canine-specific detection algorithm is designed to improve early identification of heart disease and expand access to ...

SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease. However, there ...

By combining their diagnostic and therapeutic expertise, Echosens and Boehringer Ingelheim aim to help close persistent gaps ...

This expansion will change the trajectory of MASH by focusing on early detection, diagnosis, and access to care.

Ingelheim: Boehringer Ingelheim and Eko Health have entered a strategic collaboration agreement to improve heart murmur ...

As metabolic dysfunction-associated steatohepatitis (MASH) emerges as one of the most dangerous and underdiagnosed drivers of liver failure—affecting more than 250 million people worldwide—Echosens, ...

Reduced doses in antifibrotic therapy for patients with idiopathic pulmonary fibrosis did not significantly impact outcomes, ...

Biopharmaceutical company Boehringer Ingelheim is using data and more to drive organizational change and has outlined four ...

Korea's Beringer Ingelheim recently held an event for executives and employees '60 seconds to show kidney health' As part of ...